STK33 and cancer: As the aberrant activation of Wnt/β‐catenin signaling is indispensable for maintaining cancer's malignant phenotype, our finding provides evidence that STK33 may be a key molecule in Wnt/β‐catenin signaling, and targeting STK33 is critical for the treatment of TNBC.